PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.

[1]  Stephen S. Taylor,et al.  DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors , 2019, Cancer cell.

[2]  Q. Xiang,et al.  XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy , 2018, Medicine.

[3]  A. Green,et al.  Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention. , 2018, Cancer research.

[4]  Kedar S Vaidya,et al.  Abstract 1943: PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition , 2018, Experimental and Molecular Therapeutics.

[5]  M. Lopes,et al.  Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. , 2018, Cancer cell.

[6]  Dumessa Edessa,et al.  PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers , 2017, Gynecologic Oncology Research and Practice.

[7]  Junnian Zheng,et al.  XRCC1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis through suppressing MMP-2 and MMP-9 , 2017, Oncotarget.

[8]  H. Bryant,et al.  Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase , 2017, DNA repair.

[9]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[10]  Ying Chen,et al.  Meta-analysis of XRCC1 polymorphism and risk of female reproductive system cancer , 2017, Oncotarget.

[11]  Keith W. Caldecott,et al.  XRCC1 Mutation is Associated with PARP1 Hyperactivation and Cerebellar Ataxia , 2016, Nature.

[12]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[13]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[14]  E. Swisher,et al.  Biomarkers of Response and Resistance to DNA Repair Targeted Therapies , 2016, Clinical Cancer Research.

[15]  R. London.  The structural basis of XRCC1-mediated DNA repair. , 2015, DNA repair.

[16]  C. Walsh.  Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. , 2015, Gynecologic oncology.

[17]  Alan Ashworth,et al.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.

[18]  Chunhong Hu,et al.  XRCC1 genetic polymorphism acts a potential biomarker for lung cancer , 2015, Tumor Biology.

[19]  James D. Brenton,et al.  Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.

[20]  M. Martinka,et al.  Loss of XRCC1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma , 2014, Pigment cell & melanoma research.

[21]  Samuel H. Wilson,et al.  Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition , 2014, Molecular Cancer Research.

[22]  A. Green,et al.  Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. , 2013, Human pathology.

[23]  C. Seedhouse,et al.  Clinicopathological and functional significance of XRCC1 expression in ovarian cancer , 2013, International journal of cancer.

[24]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[25]  H. Bryant,et al.  Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells , 2012, Cell cycle.

[26]  Jay W. Wright,et al.  BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence , 2012, PloS one.

[27]  Tianying Zheng,et al.  XRCC1-77T>C polymorphism and cancer risk: a meta- analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[28]  Zhao-Qi Wang,et al.  Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential. , 2009, Frontiers in bioscience.

[29]  A. Ashworth,et al.  A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.

[30]  S. Desnoyers,et al.  Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1 , 2007, BMC Molecular Biology.

[31]  T. Dawson,et al.  The Road to Survival Goes through PARG , 2005, Cell cycle.

[32]  K. Caldecott.  XRCC1 and DNA strand break repair. , 2003, DNA repair.

[33]  M. Masson,et al.  XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase and Negatively Regulates Its Activity following DNA Damage , 1998, Molecular and Cellular Biology.